诺氟沙星与甲氧苄啶-磺胺甲恶唑治疗非复杂性社区获得性尿路感染的疗效比较
Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.
作者信息
Goldstein E J, Alpert M L, Ginsberg B P
出版信息
Antimicrob Agents Chemother. 1985 Mar;27(3):422-3. doi: 10.1128/AAC.27.3.422.
Abstract
In a prospective, randomized trial, norfloxacin (400 mg perorally, twice a day) was compared with trimethoprim-sulfamethoxazole (160-800 mg perorally, twice a day) in 45 patients with uncomplicated urinary tract infections. Escherichia coli was the most common isolate. Infections due to Enterobacter spp., Proteus mirabilis, Pseudomonas spp., and Staphylococcus spp. were also treated. Norfloxacin was equivalent in effectiveness and safety to trimethoprim-sulfamethoxazole, with a cure rate of 91% at the 5- to 9-day posttherapy visit and 88% at the 4- to 6-week posttherapy visit. It was well tolerated and had a low incidence of side effects.
摘要
在一项前瞻性随机试验中，对45例单纯性尿路感染患者比较了诺氟沙星（口服400毫克，每日两次）与甲氧苄啶-磺胺甲恶唑（口服160 - 800毫克，每日两次）的疗效。大肠埃希菌是最常见的分离菌。对阴沟肠杆菌属、奇异变形杆菌、假单胞菌属和葡萄球菌属引起的感染也进行了治疗。诺氟沙星在有效性和安全性方面与甲氧苄啶-磺胺甲恶唑相当，治疗后5至9天的治愈率为91%，治疗后4至6周的治愈率为88%。其耐受性良好，副作用发生率低。
相似文献
1
Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.诺氟沙星与甲氧苄啶-磺胺甲恶唑治疗非复杂性社区获得性尿路感染的疗效比较
Antimicrob Agents Chemother. 1985 Mar;27(3):422-3. doi: 10.1128/AAC.27.3.422.
2
Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial.诺氟沙星与复方新诺明治疗单纯性尿路感染的多中心试验
J Antimicrob Chemother. 1984 May;13 Suppl B:89-94. doi: 10.1093/jac/13.suppl_b.89.
3
Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections.诺氟沙星与甲氧苄啶-磺胺甲恶唑治疗尿路感染的多中心比较研究。
Antimicrob Agents Chemother. 1985 Mar;27(3):297-301. doi: 10.1128/AAC.27.3.297.
4
Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections.诺氟沙星与复方新诺明治疗尿路感染的临床评估
Eur J Clin Microbiol. 1983 Jun;2(3):260-5. doi: 10.1007/BF02029529.
5
Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora.诺氟沙星与甲氧苄啶-磺胺甲恶唑治疗女性局部急性症状性尿路感染的对比试验及其对尿道周围和粪便微生物群的抗菌作用
Antimicrob Agents Chemother. 1984 Oct;26(4):481-4. doi: 10.1128/AAC.26.4.481.
6
Comparative efficacy and safety of nalidixic acid versus trimethoprim/sulfamethoxazole in treatment of acute urinary tract infections in college-age women.萘啶酸与甲氧苄啶/磺胺甲恶唑治疗育龄期女性急性尿路感染的疗效与安全性比较
Antimicrob Agents Chemother. 1981 Apr;19(4):598-604. doi: 10.1128/AAC.19.4.598.
7
A review of urinary tract infection in the elderly.
J Antimicrob Chemother. 1984 May;13 Suppl B:69-78. doi: 10.1093/jac/13.suppl_b.69.
8
Norfloxacin in the treatment of complicated and uncomplicated urinary tract infections. A comparative multicenter trial.
Am J Med. 1987 Jun 26;82(6B):65-9. doi: 10.1016/0002-9343(87)90621-8.
9
Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections.诺氟沙星与复方新诺明治疗下尿路感染的比较
Eur J Clin Microbiol. 1983 Jun;2(3):266-9. doi: 10.1007/BF02029530.
10
Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections.诺氟沙星、阿莫西林、复方新诺明和萘啶酸。治疗尿路感染的3天和7天疗法研究综述。
J Antimicrob Chemother. 1984 May;13 Suppl B:113-20. doi: 10.1093/jac/13.suppl_b.113.
引用本文的文献
1
Antimicrobial agents for treating uncomplicated urinary tract infection in women.用于治疗女性单纯性尿路感染的抗菌药物。
Cochrane Database Syst Rev. 2010 Oct 6(10):CD007182. doi: 10.1002/14651858.CD007182.pub2.
2
3
The place of quinolones in antibacterial therapy in hospitals.喹诺酮类药物在医院抗菌治疗中的地位。
Pharm Weekbl Sci. 1986 Feb 21;8(1):72-8. doi: 10.1007/BF01975485.
4
Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.诺氟沙星。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1985 Dec;30(6):482-513. doi: 10.2165/00003495-198530060-00003.
5
Norfloxacin penetration into human renal and prostatic tissues.诺氟沙星在人体肾脏和前列腺组织中的渗透情况。
Antimicrob Agents Chemother. 1985 Aug;28(2):349-50. doi: 10.1128/AAC.28.2.349.
6
Clinical uses of nalidixic acid analogues: the fluoroquinolones.萘啶酸类似物的临床应用：氟喹诺酮类药物。
Eur J Clin Microbiol. 1986 Apr;5(2):138-40. doi: 10.1007/BF02013968.
7
In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.A-56619、A-56620、阿米氟沙星、环丙沙星、依诺沙星、诺氟沙星和氧氟沙星对耐甲氧西林金黄色葡萄球菌的体外比较
Antimicrob Agents Chemother. 1986 Feb;29(2):325-6. doi: 10.1128/AAC.29.2.325.
8
New 4-quinolones in the treatment of urinary tract infections.
Pharm Weekbl Sci. 1986 Feb 21;8(1):46-52. doi: 10.1007/BF01975480.
9
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.氟喹诺酮类药物：人体药理学、临床应用及毒性
Antimicrob Agents Chemother. 1985 Nov;28(5):716-21. doi: 10.1128/AAC.28.5.716.
10
Quinolone antibacterial agents for the treatment of genitourinary tract infections.用于治疗泌尿生殖道感染的喹诺酮类抗菌剂。
Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1111-6. doi: 10.1007/BF01975178.
本文引用的文献
1
Mortality associated with nosocomial urinary-tract infection.与医院获得性尿路感染相关的死亡率
N Engl J Med. 1982 Sep 9;307(11):637-42. doi: 10.1056/NEJM198209093071101.
2
The pharmacokinetics and tissue penetration of norfloxacin.诺氟沙星的药代动力学及组织穿透性。
J Antimicrob Chemother. 1984 Jan;13(1):87-92. doi: 10.1093/jac/13.1.87.
3
Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin.对诺氟沙星体外药敏试验建议的质量控制限度和解释范围标准的多中心评估。
J Clin Microbiol. 1983 Oct;18(4):988-91. doi: 10.1128/jcm.18.4.988-991.1983.
4
Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.诺氟沙星（MK - 0366）治疗住院患者尿路感染
J Antimicrob Chemother. 1983 Jun;11(6):589-92. doi: 10.1093/jac/11.6.589.
5
Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections.诺氟沙星与复方新诺明治疗下尿路感染的比较
Eur J Clin Microbiol. 1983 Jun;2(3):266-9. doi: 10.1007/BF02029530.
6
Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections.诺氟沙星与复方新诺明治疗尿路感染的临床评估
Eur J Clin Microbiol. 1983 Jun;2(3):260-5. doi: 10.1007/BF02029529.
7
Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.诺氟沙星在健康志愿者以及肾、肝损伤患者中的药代动力学。
Eur J Clin Microbiol. 1983 Jun;2(3):253-9. doi: 10.1007/BF02029528.
8
Disk diffusion susceptibility tests with norfloxacin: confirmation of proposed interpretive criteria.
Eur J Clin Microbiol. 1983 Jun;2(3):242-4. doi: 10.1007/BF02029525.
9
Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma.
N Engl J Med. 1983 Jun 23;308(25):1535-6. doi: 10.1056/NEJM198306233082512.
10
Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.诺氟沙星（MK-0366）与其他十种口服抗菌药物对尿细菌分离株的体外活性比较
Antimicrob Agents Chemother. 1982 May;21(5):848-51. doi: 10.1128/AAC.21.5.848.
Zotero 插件